Peter Kuhn, PhD

University Professor, Dean's Professor of Biological Sciences and Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace and Mechanical Engineering and Urology

Image of Peter Kuhn, PhD
Is this your profile? Click to edit

Overview

Peter Kuhn joined the USC Dana and David Dornsife College of Letters, Arts and Sciences as Dean’s Professor of Biological Sciences in July 2014. Dr. Kuhn also has appointments as Professor of Medicine, Professor of Biomedical Engineering and Professor of Aerospace & Mechanical Engineering, a founding member of the Michelson Center for Convergent Biosciences at USC and is leading CSI-Cancer at USC. He is a scientist, educator and entrepreneur with a career long commitment in personalized medicine and individualized cancer patient care. He is focused on the redesign of cancer care. The first product from technology developed by Dr. Kuhn became available for prostate cancer care in June 2016. Dr. Kuhn’s strategy is to advance our understanding of the human body to improve the human condition for those affected by cancer. His research is shedding new light at how cancer spreads through the body and evolves over time. This new science will lead to a personalized care strategy that is biologically informed and clinically actionable. He is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 and his Ph.D. in 1995. He then moved to Stanford University where he joined the faculties of Medicine and Accelerator Physics as tenure track Assistant Professor. From 2002 to 2014 he established the Physics Oncology program at The Scripps Research in La Jolla, CA as tenured Associate Professor before joining USC in 2014. He has published over 200 peer scientific articles and patents resulting from his research.

Publications

  • Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy. J Immunother Cancer. 2024 02 12; 12(2).. View in PubMed
  • Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial. Clin Cancer Res. 2023 12 15; 29(24):5087-5103.. View in PubMed
  • Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma. NPJ Precis Oncol. 2023 Sep 18; 7(1):95.. View in PubMed
  • Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. Cancers (Basel). 2023 Aug 03; 15(15).. View in PubMed
  • Plasticity of circulating tumor cells in small cell lung cancer. Sci Rep. 2023 07 21; 13(1):11775.. View in PubMed
  • Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell. 2023 06 12; 41(6):1032-1047.e4.. View in PubMed
  • Simultaneous Copy Number Alteration and Single-Nucleotide Variation Analysis in Matched Aqueous Humor and Tumor Samples in Children with Retinoblastoma. Int J Mol Sci. 2023 May 11; 24(10).. View in PubMed
  • Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform. Eur J Epidemiol. 2023 May; 38(5):573-586.. View in PubMed
  • Investigation of liquid biopsy analytes in peripheral blood of individuals after SARS-CoV-2 infection. EBioMedicine. 2023 Apr; 90:104519.. View in PubMed
  • BLOODPAC: Collaborating to chart a path towards blood-based screening for early cancer detection. Clin Transl Sci. 2023 01; 16(1):5-9.. View in PubMed